(Q37677729)

21 August 2017

1 reference

title

Comparison of allergen immunotherapy practice patterns in the United States and Europe (English)

1 reference

21 August 2017

1 reference

United States of America

1 reference

1

Linda Cox

1 reference

21 August 2017

Lars Jacobsen

2

1 reference

21 August 2017

1 December 2009

1 reference

Annals of Allergy, Asthma & Immunology

21 August 2017

1 reference

21 August 2017

103

1 reference

21 August 2017

451-59; quiz 459-61, 495

1 reference

21 August 2017

6

1 reference

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Allergens of mammalian origin V. Properties of extracts derived from the domestic cat

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

The potency and antigen E content of commercially prepared ragweed extracts.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Exploiting the avian immunoglobulin system to simplify the generation of recombinant antibodies to allergenic proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

The regulatory system in europe with special emphasis on allergen products

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

European allergen extract units and potency: review of available information.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

The major allergen content of allergenic preparations reflect their biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Monoclonal antibodies against Olea europaea major allergen: allergenic activity of affinity-purified allergen and depleted extract and development of a radioimmunoassay for the quantitation of the allergen

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Aeroallergen sensitization correlates with PC(20) and exhaled nitric oxide in subjects with mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Multiallergen immunotherapy for allergic rhinitis and asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

A Double-Blind Study of the Effectiveness and Specificity of Injection Therapy in Ragweed Hay Fever

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

A controlled trial of immunotherapy for asthma in allergic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Perception and practice of sublingual immunotherapy among practicing allergists.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

The "black box" warning and allergy drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Standards for practical allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Allergen immunotherapy: a practice parameter second update

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Determinants of patient compliance with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

Factors affecting compliance with allergen immunotherapy at a military medical center

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960259-1

7 January 2021

10.1016/S1081-1206(10)60259-1

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

20084837